Serving To Educate Primary Care Clinicians On Metabolic Issues
Evidence Based Medicine Header 1
Medical Education Header 2
Peer-to-peer Exchange Header 3
Metabolic Diseases Header 4
News: Prescriber's Letter May 2015

The American Diabetes Assn will endorse more drug combo choices for patients with type 2 diabetes
   Metformin plus lifestyle changes will remain first-line...but most type 2s will need 2 or more meds to reach glycemic goals. 
   SGLT2 inhibitors or "flozins" (Invokana, etc) will be a new second-line choice...along with sulfonylureas, glitazones (Actos, etc), gliptins (Januvia, etc), GLP-1 agonists (Victoza, etc), and insulin. 

If you would like to access this month's full article on from Prescriber's letter, please click here

For the most recent full article AND to access all of the benefits of Prescriber's Letter subscribe to an option below:

Prescriber's Letter offers PCMG Members a 10% discount at two subscription levels:

The Gold Subscription is $129 and includes CME

The Platinum Subscription is $189 and provides enhanced CME and Live Webinar access 

Enter Discount Code PCMG15 when ordering either subscription HERE